LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma

Biomaterials

Volumn 34, Issue 36, 2013, Pages 9171-9182

  Zhang, Bo ^b   Sun, Xiyang ^a   Mei, Heng ^b   Wang, Yu ^a   Liao, Ziwei ^a   Chen, Jun ^a   Zhang, Qizhi ^a   Hu, Yu ^b   Pang, Zhiqing ^a   Jiang, Xinguo ^a  

^a FUDAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Brain glioma; Dual targeting; Low density lipoprotein receptor; Nanoparticles; Peptide 22; Targeting therapy

Indexed keywords

BRAIN GLIOMATA; DUAL TARGETING; LOW DENSITY LIPOPROTEINS; PEPTIDE-22; TARGETING THERAPY;

CELL DEATH; CHEMOTHERAPY; DRUG DELIVERY; FLUORESCENCE MICROSCOPY; LIPOPROTEINS; MOLECULAR BIOLOGY; NANOPARTICLES; PEPTIDES;

TUMORS;

CLATHRIN; DYE; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLE; PACLITAXEL; PEPTIDE; PEPTIDE 22 CONJUGATED NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CAVEOLA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NECROSIS; NONHUMAN; PHARMACODYNAMICS; PINOCYTOSIS; PRIORITY JOURNAL; STAINING; SURVIVAL TIME; TUMOR CELL;

MUS;

BRAIN GLIOMA; DUAL TARGETING; LOW-DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLES; PEPTIDE-22; TARGETING THERAPY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FLUORESCENCE; GLIOMA; IN SITU NICK-END LABELING; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; RATS; RECEPTORS, LDL; STATIC ELECTRICITY; TISSUE DISTRIBUTION;

EID: 84883814609     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.039     Document Type: Article

References (53)

1. Wrensch M., Minn Y., Chew T., Bondy M., Berger M.S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002, 4(4):278-299.
2. Behin A., Hoang-Xuan K., Carpentier A.F., Delattre J.Y. Primary brain tumours in adults. Lancet 2003, 361(9354):323-331.
3. Agarwal S., Sane R., Oberoi R., Ohlfest J.R., Elmquist W.F. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 2013, 13:e17.
4. Agarwal S., Manchanda P., Vogelbaum M.A., Ohlfest J.R., Elmquist W.F. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 2013, 41(1):33-39.
5. Donahue M.J., Blakeley J.O., Zhou J., Pomper M.G., Laterra J., van Zijl P.C. Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med 2008, 59(2):336-344.
6. Yan H., Wang J., Yi P., Lei H., Zhan C., Xie C., et al. Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier. Chem Commun (Camb) 2011, 47(28):8130-8132.
7. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000, 2(1):45-59.
8. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6(8):583-592.
9. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32(31):8010-8020.
10. Gao H., Qian J., Cao S., Yang Z., Pang Z., Pan S., et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2013, 33(20):5115-5123.
11. Gao H., Qian J., Yang Z., Pang Z., Xi Z., Cao S., et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 2012, 33(26):6264-6272.
12. Caruso G., Caffo M., Alafaci C., Raudino G., Cafarella D., Lucerna S., et al. Could nanoparticle systems have a role in the treatment of cerebral gliomas?. Nanomedicine 2013, 7(6):744-752.
13. Xin H., Jiang X., Gu J., Sha X., Chen L., Law K., et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32(18):4293-4305.
14. Ren J., Shen S., Wang D., Xi Z., Guo L., Pang Z., et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 2012, 33(11):3324-3333.
15. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. JControl Release 2009, 141(2):183-192.
16. Dehouck B., Dehouck M.P., Fruchart J.C., Cecchelli R. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. JCell Biol 1994, 126(2):465-473.
17. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2009, 37(1):48-57.
18. Pardridge W.M. Molecular biology of the blood-brain barrier. Mol Biotechnol 2005, 30(1):57-70.
19. Sarkar G., Curran G.L., Mahlum E., Decklever T., Wengenack T.M., Blahnik A., et al. Acarrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS One 2013, 6(12):e28881.
20. Spencer B.J., Verma I.M. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A 2007, 104(18):7594-7599.
21. Versluis A.J., Rensen P.C., Rump E.T., Van Berkel T.J., Bijsterbosch M.K. Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. Br J Cancer 1998, 78(12):1607-1614.
22. Maletinska L., Blakely E.A., Bjornstad K.A., Deen D.F., Knoff L.J., Forte T.M. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 2000, 60(8):2300-2303.
23. Firestone R.A. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 1994, 5(2):105-113.
24. Pitas R.E., Boyles J.K., Lee S.H., Hui D., Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. JBiol Chem 1987, 262(29):14352-14360.
25. Hussain M.M., Strickland D.K., Bakillah A. The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 1999, 19:141-172.
26. Li H., Gray B.D., Corbin I., Lebherz C., Choi H., Lund-Katz S., et al. MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol 2004, 11(11):1251-1259.
27. Corbin I.R., Li H., Chen J., Lund-Katz S., Zhou R., Glickson J.D., et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 2006, 8(6):488-498.
28. Crich S.G., Lanzardo S., Alberti D., Belfiore S., Ciampa A., Giovenzana G.B., et al. Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia 2007, 9(12):1046-1056.
29. Aina O.H., Sroka T.C., Chen M.L., Lam K.S. Therapeutic cancer targeting peptides. Biopolymers 2002, 66(3):184-199.
30. Malcor J.D., Payrot N., David M., Faucon A., Abouzid K., Jacquot G., et al. Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting. JMed Chem 2012, 55(5):2227-2241.
31. Okarvi S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004, 24(3):357-397.
32. Datta G., Chaddha M., Garber D.W., Chung B.H., Tytler E.M., Dashti N., et al. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000, 39(1):213-220.
33. Hajek R., Vorlicek J., Slavik M. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies minireview. Neoplasma 1996, 43(3):141-154.
34. Rowinsky E.K. Clinical pharmacology of Taxol. JNatl Cancer Inst Monogr 1993, 15:25-37.
35. Nikanjam M., Gibbs A.R., Hunt C.A., Budinger T.F., Forte T.M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. JControl Release 2007, 124(3):163-171.
36. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235(1-2):179-192.
37. Postma T.J., Heimans J.J., Luykx S.A., van Groeningen C.J., Beenen L.F., Hoekstra O.S., et al. Aphase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma. Ann Oncol 2000, 11(4):409-413.
38. Chang S.M., Kuhn J.G., Robins H.I., Schold S.C., Spence A.M., Berger M.S., et al. Aphase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American brain tumor consortium report. Cancer 2001, 91(2):417-422.
39. Lu W., Zhang Y., Tan Y.Z., Hu K.L., Jiang X.G., Fu S.K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. JControl Release 2005, 107(3):428-448.
40. Shi W., Mei H., Deng J., Chen C., Wang H., Guo T., et al. Atissue factor targeted nanomedical system for thrombi-specific drug delivery. Biomaterials 2012, 33(30):7643-7654.
41. Mei H., Shi W., Pang Z., Wang H., Lu W., Jiang X., et al. EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery. Biomaterials 2010, 31(21):5619-5626.
42. Dong Y., Feng S.S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25(14):2843-2849.
43. Olivier J.C., Huertas R., Lee H.J., Calon F., Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharm Res 2002, 19(8):1137-1143.
44. Jiang X., Sha X., Xin H., Chen L., Gao X., Wang X., et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials 2011, 32(35):9457-9469.
45. Pang Z., Gao H., Yu Y., Chen J., Guo L., Ren J., et al. Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int J Pharm 2013, 415(1-2):284-292.
46. Ke W., Shao K., Huang R., Han L., Liu Y., Li J., et al. Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 2009, 30(36):6976-6985.
47. Xia H., Gao X., Gu G., Liu Z., Hu Q., Tu Y., et al. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm 2012, 436(1-2):840-850.
48. Gynther M., Ropponen J., Laine K., Leppanen J., Haapakoski P., Peura L., et al. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. JMed Chem 2009, 52(10):3348-3353.
49. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: invitro and invivo evaluations. JControl Release 2009, 134(1):55-61.
50. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8(8):610-622.
51. Dehouck B., Fenart L., Dehouck M.P., Pierce A., Torpier G., Cecchelli R. Anew function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. JCell Biol 1997, 138(4):877-889.
52. Moyle W.R., Lin W., Myers R.V., Cao D., Kerrigan J.E., Bernard M.P. Models of glycoprotein hormone receptor interaction. Endocrine 2005, 26(3):189-205.
53. Walther T.C., Brickner J.H., Aguilar P.S., Bernales S., Pantoja C., Walter P. Eisosomes mark static sites of endocytosis. Nature 2006, 439(7079):998-1003.